MaxCyte, Inc. (MXCT)
MaxCyte, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Rockville, MD, US. The stock last traded at $1.37, up 7.03% on the session, giving a market capitalisation of $141.5M. On trailing twelve-month figures it carries a trailing P/E of -5.18, a net margin of -81.4%. Its beta of 1.48 implies it has historically moved more than the broad market.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MaxCyte, Inc. is most often compared with the following Healthcare names: